{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:37:12Z","timestamp":1787060232829,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.leukres.2022.106946","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T13:29:00Z","timestamp":1662384540000},"page":"106946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia"],"prefix":"10.1016","volume":"122","author":[{"given":"Andrew J.","family":"Klink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Gajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell L.","family":"Knoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronda","family":"Copher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106946_bib1","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML). Accessed February 17, 2021 at: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"issue":"13","key":"10.1016\/j.leukres.2022.106946_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","article-title":"Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission","volume":"2","author":"Vasu","year":"2018","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.leukres.2022.106946_bib3","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106946_bib4","first-page":"124","article-title":"Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study","volume":"10","author":"Brandwein","year":"2020","journal-title":"Am. J. Blood Res"},{"key":"10.1016\/j.leukres.2022.106946_bib5","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib6","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/cncr.21006","article-title":"Disease biology rather than age is the most important determinant of survival of patients \u226560 years with acute myeloid leukemia treated with uniform intensive therapy","volume":"103","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2022.106946_bib7","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2001-12-0354","article-title":"Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study","volume":"100","author":"Anderson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib8","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib9","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2003-05-1686","article-title":"A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group","volume":"103","author":"Rowe","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2141.2001.03043.x","article-title":"Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia","volume":"115","author":"Wahlin","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106946_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib13","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib14","first-page":"2722","volume":"91","author":"Witz","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00277-003-0650-0","article-title":"Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study","volume":"82","author":"Behringer","year":"2003","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2022.106946_bib16","unstructured":". Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia V.2.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed August 16, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"5","key":"10.1016\/j.leukres.2022.106946_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clml.2020.01.011","article-title":"A user's guide to novel therapies for acute myeloid leukemia","volume":"20","author":"Patel","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2022.106946_bib18","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106946_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106946_bib20","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106946_bib21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2022.106946_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.leukres.2022.106946_bib23","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2022.106946_bib24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib25","unstructured":"IDHIFA\u00ae (enasidenib) prescribing information. November 2020. Celgene Corporation, Summit, NJ."},{"issue":"Supplement_1","key":"10.1016\/j.leukres.2022.106946_bib26","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1182\/blood-2019-125135","article-title":"Real World Use of IDH2- targeted inhibitors in a single academic medical center experience since enasidenib FDA-approval","volume":"134","author":"Gales","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib28","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/1097-0142(19850415)55:8<1633::AID-CNCR2820550803>3.0.CO;2-W","article-title":"Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients","volume":"55","author":"Tilly","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2022.106946_bib29","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJM198312293092618","article-title":"Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia","volume":"309","author":"Mufti","year":"1983","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2022.106946_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.1984.tb02899.x","article-title":"Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction","volume":"57","author":"Leyden","year":"1984","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.106946_bib31","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.1991.9.7.1210","article-title":"Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia","volume":"9","author":"Amadori","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106946_bib32","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2004-08-2977","article-title":"Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: cancer and Leukemia Group B Study 9222","volume":"105","author":"Moore","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106946_bib33","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclas as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.leukres.2022.106946_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164587","article-title":"Value of different comorbidity indices for predicting outcome in patients with acute myeloid leukemia","volume":"11","author":"Wass","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2022.106946_bib35","article-title":"Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia","author":"Bhatnagar","year":"2020","journal-title":"Cancer Disco"},{"key":"10.1016\/j.leukres.2022.106946_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"3","key":"10.1016\/j.leukres.2022.106946_bib37","doi-asserted-by":"crossref","first-page":"dju002","DOI":"10.1093\/jnci\/dju002","article-title":"Comparison of survival outcomes among cancer patients treated in and out of clinical trials","volume":"106","author":"Unger","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.leukres.2022.106946_bib38","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1016\/j.clml.2020.06.007","article-title":"Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia","volume":"20","author":"Ravandi","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.leukres.2022.106946_bib39","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1007\/s12325-019-01003-7","article-title":"Economic and clinical burden of relapsed and\/or refractory active treatment episodes in patients with acute myeloid leukemia (AML) in the USA: a retrospective analysis of a commercial payer database","volume":"36","author":"Pandya","year":"2019","journal-title":"Adv. Ther."}],"updated-by":[{"DOI":"10.1016\/j.leukres.2023.107430","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000}}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T15:41:48Z","timestamp":1711122108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":39,"alternative-id":["S0145212622001722"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106946","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106946"}}